Ovarian Cancer

Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

The KEYLYNK-001 trial found improved PFS among patients with advanced ovarian cancer given pembrolizumab/olaparib.

Afuresertib combined with paclitaxel did not elicit PFS or OS benefits vs paclitaxel alone in patients with unselected platinum-resistant ovarian cancer.

Kathleen N. Moore, MD, MS, discusses novel antibody-drug conjugates currently in development for patients with FRα-expressing ovarian cancer.

Emily M. Hinchcliff, MD, MPH, discusses the growing role of ADCs like mirvetuximab soravtansine for the treatment of patients with ovarian cancer.

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Stéphanie Lheureux, MD, PhD, discusses technological advancements in ovarian cancer that could optimize treatment delivery, timing, and sequencing.

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

CUSP06 received fast track designation from the FDA for patients with platinum-resistant ovarian cancer.

Kathleen N. Moore, MD, MS, discusses ongoing trials of novel ADCs in ovarian cancer and the potential relevance of biomarker expression for these agents.

Kathleen N. Moore, MD, MS, details the March 2024 approval of mirvetuximab soravtansine for the treatment of FRα–positive ovarian cancer.

Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.

The FDA granted RMAT designation to gemogenovatucel-T for maintenance treatment after frontline chemotherapy in advanced HRP ovarian cancer.

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.

A final analysis of the LIGHT trial showed olaparib demonstrated higher OS rates in patients with relapsed ovarian cancer who had germline or somatic BRCA mutations.

Azenosertib (ZN-c3) monotherapy was active in heavily pretreated patients with cyclin E1–positive platinum-resistant ovarian cancer.

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Dimitrios Nasioudis, MD, discusses preclinical study findings utilizing XPO1 inhibition for TP53 wild-type low-grade serous and clear cell ovarian cancer.

The FDA has granted priority review to the NDA for avutometinib plus defactinib in KRAS-mutant recurrent low-grade serous ovarian cancer.

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.